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Abstract: Mitochondrial dysfunction has achieved an increasing interest in the field of
neurodegeneration as a pathological hallmark for different disorders. The impact of mitochondria is
related to a variety of mechanisms and several of them can co-exist in the same disease. The central
role of mitochondria in neurodegenerative disorders has stimulated studies intended to implement
therapeutic protocols based on the targeting of the distinct mitochondrial processes. The review
summarizes the most relevant mechanisms by which mitochondria contribute to neurodegeneration,
encompassing therapeutic approaches. Moreover, a new perspective is proposed based on the
heme impact on neurodegeneration. The heme metabolism plays a central role in mitochondrial
functions, and several evidences indicate that alterations of the heme metabolism are associated
with neurodegenerative disorders. By reporting the body of knowledge on this topic, the review
intends to stimulate future studies on the role of heme metabolism in neurodegeneration, envisioning
innovative strategies in the struggle against neurodegenerative diseases.
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1. Implication of Heme in Neurodegeneration
Heme is a molecule composed by protoporphyrin IX and iron produced by all the cells in
the organism, including neurons. Heme mediates a series of functions that encompass oxygen
transport, the regulation of gene expression and the modulation of enzyme activity, just to cite
the most relevant ones. Moreover, heme can also promote oxidative stress, thus performing as
a double-face molecule with both positive and negative properties [1]. This concept is also true
for neuronal cells. Indeed, on one hand heme is required for the survival and differentiation of
neuronal cells, as demonstrated by the observation that heme deficiency interferes with neurite
outgrowth in nerve growth factor (NGF)-induced PC12 cells [2,3] and results in apoptosis in PC12
pheochromocytoma cells, SHSY5Y neuroblastoma cells and U373 astrocytoma cells, as well as in rat
primary hippocampal neurons [2–4]. However, on the other hand, an excess of free-heme is associated
with neurodegeneration. The large amount of hemoglobin and heme released in the brain during
intracerebral or subarachnoid hemorrhages promotes oxidative stress, lipid peroxidation, inflammatory
response and finally, neuronal cell death [5–7]. Moreover, loss of the heme scavenger hemopexin
(Hx) causes defective myelination in mice [8–10]. Furthermore, impairment of cellular heme export
reduces SHSY5Y cells survival [11]. Together, these data indicate that both heme deficiency and
excess are deleterious for the survival of neuronal cells (Figure 1), thus suggesting that heme levels
must be finely controlled both at the systemic and cellular level. At the systemic level, circulating
free-heme is scavenged by the plasma proteins haptoglobin and hemopexin [6–8,10,12–14]. However,
at cellular level, the amount of intracellular free-heme (labile heme or heme regulatory pool) is regulated at
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multiple steps: heme synthesis, incorporation into hemoproteins, catabolism, import and export [1,15].
Although this tight regulation has been extensively studied in non-neuronal cells, similar mechanisms
likely occur in the nervous system. Indeed, the main proteins involved in the control of labile heme
are also expressed in the nervous system [16].
Figure 1. Implication of heme in neurodegeneration. Both heme excess and heme deficiency contribute
to neurodegeneration. Heme released during hemorrhages leads to inflammation, lipid peroxidation
and oxidative stress; the loss of the heme scavenger Hx causes defective myelination of axons;
the impairment of intracellular heme export by FLVCR1a is associated with increased oxidative
stress. On the other hand, heme deficiency, due to defective synthesis, leads to mitochondrial decay
and the blocking of neurite growth. These events all result in neuronal cell death. In the figure, neurons
are represented as the main target for heme-mediated effects; however, other cell types of the nervous
system could be affected by the same phenomena.
Neurodegenerative disorders are a common and growing cause of mortality and morbidity
worldwide [17]. Recently, a series of rare neurodegenerative disorders have been directly linked
to alterations of heme metabolism (see Table 1). Defective heme synthesis causes porphyrias, some
of which are associated with a wide array of neurological disturbances involving both the central
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and peripheral nervous systems (neuropathic porphyria). Neuropathic porphyria includes acute
intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP) and
5-aminolevulinate dehydratase deficiency (ALAD deficiency) [18–20]. Furthermore, reduced heme
synthesis has been observed in Friederich Ataxia (FRDA), an autosomal recessive disorder caused by
mutations in Frataxin (FXN), a mitochondrial iron chaperone involved in iron-sulfur (Fe-S) clusters
and heme biosynthesis [21–24]. Finally, reduced heme synthesis has been observed during aging [4,25].
Table 1. Rare neurodegenerative disorders linked to defective heme metabolism.
Disease Gene Inheritance Clinical Features OMIM
ALAD deficiency 5-aminolevulinatedehydratase (ALAD)
autosomal
recessive
Neuropathic Porphyria: acute neurovisceral
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Subgroup C Receptor 1
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autosomal








Proliferative glomerular vasculopathy in the
central nervous system associated with severe
hydrocephaly, ventriculomegaly, cortical
thinning and hypoplastic cerebellum.
225790
In addition, other rare neurodegenerative disorders have been associated with defective heme
transport across membranes. Several proteins are involved in this process [1,15]. Among them, Feline
Leukemia Virus Subgroup C Receptor 1 (FLVCR1) and 2 (FLVCR2) are implicated in heme export
and import, respectively [11,26–31]. Mutations in the heme exporter FLVCR1 are associated with
three distinct disorders affecting the sensory nervous system: posterior column ataxia and retinitis
pigmentosa (PCARP) [32–34], non-syndromic retinitis pigmentosa (RP) [35,36] and hereditary sensory
and autonomic neuropathy (HSAN) [11,37]. Mutations in the heme importer FLVCR2 are responsible
for the Fowler syndrome, a proliferative glomerular vasculopathy [30,38,39].
Furthermore, several lines of evidence suggest that heme may also contribute to the pathogenesis
of common neurodegenerative disorders. The deregulation of enzymes critically involved in heme
synthesis has been reported in both Alzheimer’s disease (AD) and Parkinson’s disease (PD). Reduced
5-aminolevulinate synthase 1 (ALAS1) and porphobilinogen deaminase (PBGD) mRNA were observed
in AD brains [40], suggesting decreased heme synthesis rates in AD. Moreover, heme deficiency has
been reported in the brain of patients with AD [41]. It has been proposed that heme deficiency may
arise from either decreased heme synthesis rates or heme depletion as a consequence of heme binding
to amyloid-β [41–43]. However, increased Ferrochelatase (FECH) levels were reported in another
study [41].
Heme binding to α-Synuclein has also been reported [44], suggesting that heme depletion
may also occur in PD. In addition, blood transcriptomic meta-analysis showed downregulation
of 5-aminolevulinate synthase 2 (ALAS2) and FECH in PD [45]. However, within PD erythroid cells,
α-synuclein gene (SNCA) was co-expressed with crucial enzymes involved in heme metabolism,
including ALAS2, FECH and biliverdin reductase B (BLVRB) [46]. Moreover, increased striatal
5-aminolevulinate dehydratase (ALAD) activity was observed in the MPTP-induced mouse model
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of PD, indicative of increased heme synthesis rates [47]. It is difficult to conclude from these studies
whether heme synthesis is increased or reduced in AD and PD. Data are still controversial due to the
low amount of human samples analyzed and the different experimental approaches adopted. Further
studies are required to definitively determine heme synthesis rates in these pathological conditions.
Mouse models of AD and PD will be extremely useful to analyze in detail the role of heme metabolism
in these disorders.
A role for heme derived from extracellular sources in the pathogenesis of neurodegenerative
disorders has also been proposed. The heme scavenger Hx has been found strongly increased in the
cerebrospinal fluid of AD patients [48–50]. Similarly, altered expression of the hemoglobin scavenger
haptoglobin was shown in AD [51,52], PD [53,54] and Huntington’s disease (HD) [55]. The induction
of heme oxygenase 1 (HO1), the enzyme responsible for heme degradation, is common in patients
affected by neurodegenerative conditions. Although HO1 is induced by a plethora of stimuli, it has
been proposed that HO1 overexpression in AD and PD may be a consequence of increased brain-blood
barrier permeability and hemoglobin-derived heme levels in AD and PD [16]. Moreover, increased
expression of HO1 was reported in a mouse model of amyotrophic lateral sclerosis (ALS) [56] and ALS
patients [57].
All the reported examples highlight the importance of the maintenance of heme homeostasis in
the context of neurodegeneration. However, the molecular mechanisms underlying these disorders
and the precise mechanism through which heme participates to them remains elusive and requires
further investigations.
2. Role of Mitochondria in Neurodegenerative Diseases
Neurodegeneration can be elicited by several systems. Among them, mitochondrial-dependent
processes have become increasingly relevant [58–63]. Several mechanisms account for mitochondria-
dependent neurodegeneration (see Figure 2 for a graphic list of them) and below we attempt to
summarize the most important ones.
Figure 2. Mitochondrial dependent mechanisms in neurodegeneration. Mitochondria contribute to
neurodegeneration by several mechanisms, including alterations in calcium homeostasis, mitochondrial
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biogenesis (mitobiogenesis), mitochondrial dynamics, metabolism and mitophagy. Moreover,
mutations in mitochondrial DNA (mtDNA) and inappropriate activation of apoptosis can be
alternative mechanisms. Finally, additional systems include mutations in nuclear DNA (nDNA)
at the level of genes encoding for mitochondrial proteins, the compromised exchange of
mitochondria-derived vesicles (MDVs) among mitochondria and peroxisomes and the inefficient
interaction among mitochondria and the endoplasmic reticulum at the level of mitochondrial associated
membranes (MAMs).
2.1. Mutations on Mitochondrial DNA (mtDNA) Genes
Mitochondria contain their own genome, which is made of multiple copies of a circular double
stranded molecule, which is 16.6 kb long in humans. It comprises 37 genes, 13 encoding for proteins
involved in adenosine triphosphate (ATP) production and the other 24 encoding for two rRNAs
and 22 tRNAs. Cells contain thousands of molecules of mtDNA and the majority of them have the
same sequence, a condition known as homoplasmy. Inefficient mtDNA repair, localized oxidative
environment and increased replication, however, can promote mtDNA mutations that, due to the
polyploidy nature of mtDNA, often co-exist with their wildtype counterpart in various proportions
(a condition termed heteroplasmy). mtDNA mutations are usually responsible for defects in the
respiratory chain functions, but only if they are present above a certain threshold level.
The replication of mtDNA occurs independently on cell cycle, and a particular mtDNA molecule
may be strongly replicated (or not at all) during cell division. Moreover, replication occurs also in
postmitotic cells. These phenomena account for the clonal expansion of mutated mtDNA molecules
and in association with heteroplasmy, result in mosaicism, with the levels of mutated mtDNA varying
dramatically between tissues in the same organism and in different regions of the same tissue.
Somatic mtDNA mutations accumulate during a person’s lifetime and undergo clonal expansion,
so aging is typically associated with mosaic occurrence of respiratory chain-deficient cells in tissues [64].
Mitochondrial reactive oxygen species (ROS) production is the major cause for the higher mtDNA
nucleotide instability when compared with nDNA.
Mitochondrial DNA mutations potently affect tissue that require a large amount of ATP to
function, such as heart and brain. Some haplogroups [65] (evolutionary selected population subgroups
carrying neutral single-base pair variants of mtDNA) have been associated with susceptibility to a
variety of human diseases, including age-related neurodegenerative disorders such as PD and AD.
Moreover, inherited point mutations and sporadic rearrangements on mtDNA have been described in
association with neurodegeneration [65–69].
Although the presence of mtDNA deletions below a certain threshold is not sufficient to
induce PD, small changes inside the genome of mitochondria could represent a risk factor for this
pathology [70–74]. In addition, the accumulation of mutations in mtDNA over the course of PD has
been observed to correlate with severity and burden of the disease [75]. Accumulation of mtDNA
damage is also considered a possible mechanism of neurodegeneration over the course of HD [76].
Moreover, mtDNA mutations have been associated with AD [77], although the degree of mtDNA
damage does not seem to correlate with the severity of AD symptoms [78].
As stated before, mtDNA alterations often result in defects on a particular component of the
electron transport chain (ETC). The three main mechanisms through which mtDNA damage can
contribute to neurodegeneration are therefore consequences of ETC alteration and include the decrease
of ATP synthesis, the increase of ROS production and the enhanced sensitivity to neurotoxins associated
to ETC disruption.
2.2. Mutations on Nuclear DNA Genes Encoding Proteins Crucial for Mitochondrial Functionality
Besides mutations on mitochondrial DNA, mutations in nuclear DNA (nDNA) at the level of
genes encoding for mitochondrial proteins have also been associated with neurodegenerative disorders.
For example, many of the identified ALS genes have a role in mitochondrial-associated functions
(see [79] for a comprehensive description on this topic). In addition, mitochondrial dysfunction
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and oxidative stress in PD have been linked to mutations in genes encoding for parkin RBR E3
ubiquitin protein ligase (PRKN, commonly referred to as parkin), PTEN induced putative kinase 1
(PINK1, a protein that acts in the same pathway of parkin) and parkinsonism associated deglycase
(DJ-1) [80], just to cite some of them. Parkin promotes autophagy of damaged mitochondria [81]
and its deficiency is associated with defects in mitochondria morphology [82] and low levels of
proteins involved in mitochondrial functions, thus resulting in decreased mitochondrial respiration [83].
Similarly, mutations in PINK1 gene lead to decreased mitochondrial respiration [84] and alterations in
mitochondria functions [85–88]. Regarding DJ-1, this protein localizes into mitochondria [89] and exerts
crucial antioxidant functions [80,90–92]. Mutations in DJ-1 impair mitochondrial respiration, reduce
mitochondrial membrane potential, increase ROS within the mitochondria and alter mitochondrial
morphology [93]. Also, nDNA encoded proteins implicated in AD, like presenilin-1 and presenilin 2
(PSEN1 and 2) are related to mitochondria [94,95].
2.3. Alterations of Mitochondrial Dynamics (Fusion, Fission, Motility)
Mitochondria are not rigidly structured. They form a complex reticulum that undergoes regulated
processes of fusion (the combination of two smaller mitochondria into a single organelle) and fission
(the division of one large mitochondrion into two smaller fragments). Fusion allows mitochondria
to mix their contents, enabling protein complementation, mtDNA repair and equal distribution of
metabolites. Fission facilitates equal segregation of mitochondria into daughter cells during cellular
division, enhances the distribution of mitochondria along cytoskeletal tracts and participates in the
targeting of damaged segments of mitochondria to the autophagic process. Fusion and fission also
contribute to the movement of mitochondria necessary for mitochondria distribution along neuronal
axons and dendrites. Mitochondrial dynamics are crucial for neurotransmission, synaptic maintenance
and neuronal survival. Proper mitochondrial trafficking is particularly important in neurons compared
to other cell types, due to their exceptional cellular morphology. Indeed, neurons extend their axons
and dendrites for very long distances that, in the case of human peripheral nerves or corticospinal
tracts, extend up to a meter. Thus, the neuron represents an extreme case of mitochondrial distribution:
dysfunctions in mitochondrial distribution that are not dangerous for other cells could be fatal for
neuronal survival [96].
Alterations in mitochondria motility have been reported in several neurodegenerative disorders
and neuropathies [97,98]. Aberrant activity of the fission-fusion machinery contributes to the
pathogenesis of PD [99–102]. Moreover, alterations of mitochondrial dynamics have been observed in
AD [61,102] and HD [100,103]. Particularly in HD, mitochondrial fission is promoted and mitochondrial
fusion proteins are downregulated as the severity of the pathology increases [104]. Finally, defects in
mitochondrial dynamics and disruption of the axonal transport of mitochondria have been reported in
ALS [60,105–107].
2.4. Inappropriate Activation of Cell Apoptosis by Mitochondria
Mitochondria are pivotal organelles for the execution of apoptosis. The inappropriate activation
of apoptosis leads to the disruption of the cellular proliferation-death balance. Neurodegenerative
disorders are believed to partly depend on alterations of this equilibrium. PINK1 loss-of-function
mutations lead to early signals for apoptosis, promoting neurodegeneration in the context of
PD [108]. Moreover, the low levels of PTPA (phosphotyrosyl phosphatase activator) observed in
AD affected-people contribute to induce cell apoptosis in the brain of these patients [109]. Furthermore,
caspase-6, an effector of the caspase-dependent apoptotic pathway, is known to be involved in the
cleavage of mutant huntingtin resulting in neurodegeneration in HD patients [110]. Finally, in ALS the
mutant SOD1 can trigger cytochrome c release from mitochondria to operate apoptosis [111].
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2.5. Alteration of Mitochondria-Dependent Ca2+ Homeostasis
An additional neurodegenerative mechanism related to dysfunctions of mitochondria concerns
the modulation of calcium. Mitochondria are involved in Ca2+ homeostasis as they are able
to both accumulate and release Ca2+. Mitochondrial Ca2+ concentration is fundamental for
the regulation of specific mitochondrial key functions, such as the apoptotic process and the
activity of several mitochondrial enzymes. The deregulation of Ca2+ homeostasis is a hallmark
of different neurodegenerative diseases including PD, AD, HD and ALS [112,113]. Moreover,
alterations of calcium levels have been observed in neuropathies. Neuropathic pain phenotypes
include chemotherapy induced neuropathy, diabetic neuropathy, human immunodeficiency virus
(HIV)-associated neuropathy and Charcot-Marie-Tooth neuropathy. Neuropathies have been associated
with mitochondrial dysfunctions [63], and particularly in diabetic neuropathy, impaired cellular
calcium homeostasis, including alterations in mitochondrial Ca2+ concentration, has been reported.
Indeed, in the context of diabetes, sensory neurons, above all the lumbar dorsal root ganglia neurons
(which have the longest axons), show an increased intracellular Ca2+ concentration that triggers
elevated mitochondrial Ca2+ levels. This condition induces mitochondrial membrane depolarization
and can favor the generation of reactive oxygen species (ROS) and oxidative stress, as well as alterations
in mitochondrial functionality that can ultimately lead to neuronal damage [114].
2.6. Additional Alterations of Mitochondrial-Related Processes: Biogenesis, Mitophagy, Mdvs Exchange,
Interaction with Mams, Control of Cellular Metabolism
Besides the mechanisms reported above, a series of additional mechanisms involving
mitochondria have been described. Among them, neurodegeneration has been associated with the
impairment of mitochondrial biogenesis. Particularly, the deficit of peroxisome proliferator-activated
receptor gamma coactivator-1α (PGC-1α), a key regulator of mitochondrial biogenesis, has been
associated with HD, PD and AD [115–120].
Mitophagy is also linked to neurodegenerative disorders [121–123]. Mitophagy is the selective
autophagic process responsible for the elimination of damaged or excess mitochondria. In this process,
a peculiar role is played by PINK1, that recruits parkin to dysfunctional mitochondria, where it
induces their degradation by mitophagy [124]. Thus, it is not surprising that in addition to other
neurodegenerative disorders, defective mitophagy is highly implicated in PD and is considered one
of the major pathological mechanisms of mitochondrial dysfunction in autosomal recessive forms of
PD [125].
Mitophagy is a cellular process that eliminates whole mitochondria, but other mechanisms exist
to partially eliminate portions or components of mitochondria [122]. Mitochondria-derived vesicles
(MDVs) exchange between mitochondria and peroxisomes represent one of these possible mechanisms.
MDVs are crucial for the transport of cargo from mitochondria to peroxisomes. This process is
regulated by the retromer complex. Studies on vacuolar protein sorting 35 (VPS35), a component of
the retromer complex, indicate that mutations or alterations in VPS35 expression are associated to
PD [126,127]. Moreover, it has been demonstrated that Parkin and PINK1, two genes highly implicated
in PD, play crucial roles in the control of this process [128,129].
Other than with peroxisomes, mitochondria also physically interact with other subcellular
organelles to ensure efficient and rapid metabolism and signaling. For example, the interaction
between mitochondria and the endoplasmic reticulum (ER) occurs at the level of MAMs (mitochondrial
associated membranes), a subdomain of the ER. The proteins involved in neurodegenerative diseases
such as DRP1 (dynamin related protein 1) and MFN2 (mitofusin 2) are enriched in MAMs [130,131]
and the perturbation of mitochondria-ER contacts has been described in neurodegenerative disorders,
including PD, AD and ALS [132].
A further mitochondrial-dependent mechanism has been highlighted in neurodegeneration. This
is the impairment of cell metabolism [133]. Mitochondria are the main energy-producing organelles
of the cell, thus any process impairing mitochondrial functionality may lead to metabolic switching
Pharmaceuticals 2018, 11, 87 8 of 21
aimed to compensate for their decreased ATP production. Among the different neurodegenerative
disorders, many lines of evidence suggest that mitochondria-dependent mechanisms are responsible
for the metabolic changes observed in dopaminergic neurons in the context of PD. Mitochondrial ROS
are particularly abundant in dopaminergic neurons due to dopamine oxidative metabolism, enhanced
Fenton’s reaction initiated by the high iron content of these cells, and the high rate of ATP production
required to sustain the activity of a particular L-type voltage dependent Ca2+ channel expressed
by these neurons. An excess of mitochondrial ROS can induce a series of cellular modifications,
including hypoxia inducible factor 1α (HIF1α)-dependent up-regulation of glucose transporters [134],
favoring the switch of energy metabolism towards glycolysis. When sustained for a long period,
this metabolic change can be deleterious for dopaminergic neurons. Indeed, neurons need to deliver
glucose in the pentose phosphate pathway (PPP), a process that produces NADPH (nicotinamide
adenine dinucleotide phosphate), crucial for the recycling of the antioxidant glutathione. PPP is
especially important in neurons as these cells show less robust antioxidant systems and are more
vulnerable to oxidative stress than other cell types. Switching from PPP to glycolysis promotes
oxidative stress and, consequently, neurodegeneration [135].
3. Heme and Mitochondrial Dysfunction Related to Neurodegenerative Diseases
The examples reported above sustain the notion that mitochondrial dysfunctions play a critical
role in neurodegenerative disorders. The mitochondrion is a critical organelle for cells, representing a
crossroad for a plethora of reactions contributing to a variety of metabolic processes, including heme
metabolism. Considering the impact of impaired heme homeostasis in several neurodegenerative
disorders and the interesting potential that heme takes on for the research in the context of
neurodegeneration, it is curious to notice that heme is an under-investigated molecule in the field. This
discrepancy could be due to the lack of knowledge on the possible systems through which heme can
influence pivotal processes implicated in neurodegeneration. Among the possible ways, it is tempting
to speculate that heme could directly or indirectly affect many of the mitochondrial-dependent
mechanisms of neurodegeneration described in the previous paragraphs. Indeed, the relationship
between heme and mitochondria is based on several elements (Figure 3): heme is produced through a
series of reactions that occur partly in the mitochondria and partly in the cytosol [136]; heme acts as
a cofactor for cytochromes c and cytochromes in complexes II-III-IV of the mitochondrial ETC [137];
heme has been reported to directly or indirectly influence ATP translocation between mitochondria
and cytosol [138–140] mediated by adenine nucleotide translocases (ANTs); finally, heme biosynthesis
is considered a cataplerotic pathway for the Kreb’s cycle due to the fact that the first step of heme
production consumes succynil-CoA [141,142]. Thus, modulation of heme homeostasis can affect
mitochondrial functions.
Considering the mechanisms by which mitochondria contribute to neurodegeneration, it is
interesting to note that heme levels can influence iron homeostasis, and both iron deficiency and iron
excess are reported to cause damage on mitochondria [143,144] and on mitochondrial DNA [145,146].
Moreover, a decrease in heme itself leads to mitochondrial decay [4,147].
Furthermore, a connection exists between heme and nDNA genes encoding mitochondrial
proteins typically implicated in neurodegenerative disorders. Indeed, it has been demonstrated
that amyloid precursor protein, particularly when mutated, interacts and negatively regulates
the heme-degrading enzyme HO1 [148]. Also PINK1 mutation is related to alterations in HO1
expression [149]. Moreover, DJ1 regulates nuclear factor-E2-related factor 2 (NRF2) [150], a key
transcription factor for the induction of HO1 expression [151].
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Figure 3. The “heme-mitochondria” relationship and the putative heme-related targets for the therapy
of neurodegenerative disorders. Heme and mitochondria share a strong relationship based on several
elements: heme synthesis occurs partly in the mitochondrion and acts as a cataplerotic pathway for
the Kreb’s cycle; heme is a cofactor for cytochromes c and cytochromes in complexes II-III-IV of the
mitochondrial ETC [137]; heme influences the ATP translocation between mitochondria and cytosol
mediated by adenine nucleotide translocases (ANTs); heme export influences calcium (Ca2+) flux in
mitochondria. Therefore, modulation of heme metabolism can lead to modification of mitochondrial
functions. The control of intracellular heme levels is achieved by a balance among synthesis, catabolism
and proper trafficking of heme. Thus, all these processes (highlighted with red boxes in the figure)
represent putative good targets for the therapy of neurodegenerative disorder.
In addition, heme and the heme-degrading enzyme HO1 are implicated in the regulation of
mitophagy, mitochondrial biogenesis and morphology [152–154].
In endothelial cells, it has been demonstrated that alterations in heme metabolism, in addition to
promoting lipid peroxidation and activation of autophagy, induce mitophagy and apoptosis, indicating
mitochondrial dysfunction [155]. Similarly, FLVCR1 loss is associated with alterations in mitochondrial
morphology in human microvascular endothelial cells [26].
Furthermore, FLVCR1-deficient HeLa cells show impaired mitochondrial calcium uptake [156].
These data have been obtained in non-neuronal cells. However, similar mechanisms could also
occur in neuronal cells.
Finally, compromised ETC complexes activity has been observed in the brain of a mouse model
for acute intermittent porphyria, a type of porphyric neuropathy caused by alterations of heme
biosynthesis [157]. Moreover, in three cases of Fowler syndrome it was suggested to be the presence of
a defect in complex III and IV of the ETC [158,159].
These examples directly suggest that a connection between heme-mitochondria-
neurodegeneration exists and open the possibility that future studies on this topic will further
strengthen this notion.
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4. Current Therapies and Potential Future Approaches to Face Mitochondrial Dysfunction in
Neurodegenerative Diseases
Currently, there is no cure for reversing neurodegeneration and the treatment of
neurodegenerative disorders is mainly symptomatic [160]. In order to face neurodegeneration,
several pathways could be targeted to improve and/or restore mitochondrial functions, including
mitochondrial biogenesis and metabolic flexibility, mitochondrial dynamics and mitophagy [161].
There are several pharmacological approaches to induce mitochondrial biogenesis and metabolic
flexibility, that is the ability to switch from one fuel source to another. Several compounds have been
generated to target the upstream sensors of energy production, including AMP-activated protein
kinase (AMPK), mammalian target of rapamycin (mTOR) and sirtuins, or downstream transcriptional
factors and co-factors, such as nuclear receptors, nuclear respiratory factor 1 (NRF1) and mitochondrial
transcription factor A (TFAM) [161]. The therapeutic potential of these drugs has been evaluated mostly
in the context of metabolic diseases, but also seems promising for neurodegeneration. For example,
resveratrol is a natural compound that mimics caloric restriction and activates the sirtuin family
of histone deacetylases. In humans, resveratrol improves mitochondrial function in obese patients
and type 2 diabetes [162]. Furthermore, resveratrol counteracts neurodegeneration in worms and
mice [163].
As described above, the disruption of the balance between mitochondrial fusion and fission
contributes to neurodegeneration. Therefore, targeting mitochondrial dynamics represents another
important strategy to improve mitochondrial function in neurodegenerative diseases. Strategies
aimed at increasing mitochondrial fusion or inhibiting mitochondrial fission might improve
mitochondrial function and are therapeutically interesting. The promotion of mitochondrial fusion
by the overexpression of key components of the fusion machinery, like MFN2 or OPA1, rescues ATP
production and mitochondrial morphology in a cellular model of PD [164]. Similar results were
obtained with the inhibition of fission through the genetic deletion of DRP1 [164,165]. Although the
understanding of the regulation of mitochondrial dynamics is still in its infancy, novel compounds have
been identified to promote fusion or inhibit fission [166]. M1 hydrazone [167] and S3-derivative [168]
promote mitochondrial fusion in cells deficient for mitofusin 1 (MFN1) and MFN2. Mdivi-1
(mitochondrial division inhibitor) attenuates fission in yeast and mammalian cells by inhibiting DRP1.
In vitro, Mdivi-1 delays apoptosis by inhibiting mitochondrial outer membrane permeabilization
and blocking cytochrome c release from mitochondria [169]. The therapeutic potential of Mdivi-1
seems promising for neurodegenerative disorders. Indeed, the administration of Mdivi-1 in mouse
and cellular models of PD attenuates disease-associated phenotypes [165,170]. Although initially
reported as an inhibitor of fission, Mdivi-1 was recently reported to reversibly inhibit complex I in a
DRP1-independent manner [171]. The complete inhibition of complex I in vivo would be expected to
cause neurodegeneration. Indeed, rotenone completely inhibits complex I, induces ROS levels and
causes parkinsonian neurodegeneration in mice [172]. In contrast, Mdivi-1 lacks neuronal toxicity
in vivo and is neuroprotective. This is likely due to the ability of Mdivi-1 to attenuate complex
I-dependent reverse electron transfer (RET)-mediated ROS production. Indeed, Mdivi-1 fails to
increase ROS levels in intact neurons and in isolated brain mitochondria [171].
The accumulation of dysfunctional mitochondria is another key event in several neurodegenerative
conditions [173,174]. In this context, mitophagy is essential for the maintenance of mitochondrial
integrity. As stated before in this review, the impairment of autophagy/mitophagy is
common in neurodegenerative disorders. Therefore, mitophagy may be an additional pathway
amenable for therapeutic intervention to ameliorate mitochondria function and counteract
neurodegeneration [161,175]. Interestingly, both genetic and pharmacological induction of the
mitochondrial autophagy receptor Nip3-like protein X (NIX) restores mitophagy in patient-derived
fibroblasts [176].
Considering the crucial role of heme in maintaining mitochondrial function, it is tempting
to speculate that targeting heme metabolism might be a promising strategy for the treatment of
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neurodegenerative diseases. Multiple approaches can be used to target heme metabolism (Figure 3);
theoretically, targeting any of the enzymes involved in the heme biosynthetic pathway or proteins
involved in the control of the intracellular heme pool may be a good strategy. Among these methods,
HO1 represents a potentially interesting target. Due to its anti-oxidant and anti-inflammatory
properties, HO1 plays a well-established neuroprotective role. The improvement of HO1 expression has
been initially proposed for neurodegenerative conditions [177]. However, it has been reported that the
overexpression of HO1 induces oxidative mitochondrial damage [178,179] and macroautophagy [179]
in cultured astroglia. More importantly, HO1 induction has been associated with the later phases of
neurodegeneration [180] and the deletion of HO1 has been proposed as a therapeutic option [181].
HO1 activity can be suppressed by synthetic metalloporphyrin compounds that unfortunately present
important limitations [182]. However, novel HO1 inhibitors have been synthesized to overcome these
side effects. Interestingly, these inhibitors confer neuroprotection in a mouse model of AD [182].
Considering the complex role of HO1 in neurodegeneration and the still controversial data reported in
literature [180], further work is needed to fully elucidate the therapeutic potential of HO1 targeting.
Recently, long-term 5–aminolevulinic acid (ALA) treatment has been exploited as a therapeutic
approach in a mouse model of AD. Omori C. et al. reported that the oral administration of ALA
increased cytochrome c oxidase (COX) activity and protein expression as well as mitochondrial
membrane potential in the brain of treated mice [183]. Additional studies are required to understand
more in detail the functional consequences of ALA administration in AD pathogenesis and the
translation of this therapeutic approach to other neurodegenerative disorders. Considering that ALA
formulations are already used for photodynamic therapy in a variety of cancer types [184], results
obtained by Omori C. et al. are extremely encouraging for therapeutic purposes and further research
in this direction is desirable.
5. Conclusions
The information reported over the course of the present review showed that mitochondria
participate to neurodegenerative disorders by different mechanisms, encompassing DNA mutations,
mitobiogenesis, mitophagy, mitochondrial dynamics, metabolism and mitochondrial interactions with
other organelles. The literary contributions on the role of mitochondria in neurodegeneration are
constantly growing and the present review attempted to make an excursus on the most important
mechanisms by which these crucial organelles contribute to neurodegenerative diseases, with
the awareness that not all the wide literature on this topic has been covered. Some of these
mechanisms are currently considered as strategic targets for pharmacological interventions to
counteract neurodegeneration. However, the investigation on additional elements contributing to
the control of mitochondrial functions in neuronal cells will offer a wider window of intervention.
In this perspective, heme metabolism provides an interesting opportunity. Indeed, as reported above
in the review, heme participates to crucial processes occurring in mitochondria, influencing their
functions and properties. The tight relationship between heme and the mitochondrion has been
curiously underestimated and poorly investigated in the context of neurodegeneration. However, the
implication of heme in crucial mitochondrial functions and the involvement of heme in a subset of
neurodegenerative diseases strongly suggest an implication of heme in these disorders.
The comprehension of these mechanisms will allow the consideration of possible therapies
based on the targeting of heme metabolism as an additional option to promote mitochondrial
function. Alternatively, targeting heme metabolism may improve the efficacy of other drugs
targeting mitochondria. The hope is that the understanding of the role of heme in mitochondria
and its implication in neurodegeneration will open new perspectives in the struggle against
neurodegenerative diseases.
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